State
20,072 recalls have nationwide distribution and so reach Iowa. 0 additional recalls listed Iowa specifically in their distribution scope.
Most US product recalls have nationwide distribution — the manufacturer ships into every state and the recall sweeps the same way. We include those in this listing because they affect Iowa consumers even though the source notice doesn’t name the state. State-specific recalls are usually for products with regional distribution (a regional dairy, a local store brand) or where the agency was able to narrow the affected shipments to specific destinations.
If you’re checking whether a recall affects your purchase, the recall detail page lists the exact production lot codes, UPCs, and best-by dates. Match those against your package — distribution scope is a starting filter, not the final answer.
Pending LLM rewrite. Source: FDA_DRUG D-0342-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0312-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0336-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0353-2025.
Medline is recalling 20 units of ReNewal Coblator II ENT devices because drip chambers may disconnect from saline tubing under tension, potentially disrupting fluid delivery during procedures.
Pending LLM rewrite. Source: FDA_DEVICE Z-1548-2025.
Glenmark Pharmaceuticals is recalling acetaminophen-ibuprofen tablets due to manufacturing quality deviations. No illnesses reported. Distributed nationwide via Amazon and Walmart.
Glenmark Pharmaceuticals is recalling Lacosamide 150mg tablets nationwide due to manufacturing quality deviations. Consumers should contact their pharmacy or healthcare provider regarding their supply.
Pending LLM rewrite. Source: FDA_DRUG D-0328-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0356-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0325-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0334-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0352-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0314-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0327-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0354-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0316-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0358-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0349-2025.
Glenmark Pharmaceuticals is voluntarily recalling Indomethacin Extended-Release Capsules (75mg) distributed nationwide due to Good Manufacturing Practice deviations identified during FDA oversight.
Glenmark Pharmaceuticals is voluntarily recalling Rosuvastatin Calcium 40mg tablets nationwide due to manufacturing practice deviations. The recall affects specific lot numbers expiring February through June 2026.
Glenmark Pharmaceuticals is voluntarily recalling Cetirizine HCL 10mg tablets distributed nationwide. The recall was initiated due to Current Good Manufacturing Practice deviations.
Glenmark Pharmaceuticals is recalling Ranolazine Extended-Release 1000mg tablets (Lot 17240040) nationwide due to manufacturing deviations. This is a voluntary, firm-initiated recall.
Glenmark Pharmaceuticals Inc. USA is recalling Clindamycin Hydrochloride Capsules, USP 300mg due to CGMP deviations. The product has been distributed nationwide.
Glenmark Pharmaceuticals is recalling solifenacin succinate 10mg tablets nationwide due to manufacturing process deviations. The voluntary recall affects specific lot numbers distributed across the United States.